Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Engineered erythrocytes and erythrocyte extracellular vesicles for advanced Photodynamic and Sonodynamic therapy

Objective

ERYSO aims to develop innovative therapeutic solutions based on photodynamic (PDT), and sonodynamic (SDT) therapies using
engineered red blood cells (RBCs) and extracellular vesicles (EVs) derived from RBCs in combination with magnetothermal (MHT)
therapy. Both RBCs and RBC-derived EVs are characterized by their ability to transport hemoglobin, the body's natural oxygen carrier,
and exhibit long circulation times, providing a unique advantage for therapeutic delivery. Encapsulating photosensitizers (PSs) and
engineering these carriers for tumor targeting addresses a major limitation of existing PDT and SDT solutions, hypoxic tumor regions, by delivering oxygen directly to these areas, enhancing therapy efficacy. Combining PDT and SDT with MHT further amplifies
therapeutic outcomes, providing a multimodal approach to tumor eradication.
Magnetic nanoparticles for MHT or titanium oxide nanoparticles for SDT will be encapsulated in the carriers to enable combination of
therapies. Tumor targeting will be achieved by functionalizing RBC glycocalyx with targeting peptides or incorporating functionalized
lipids into EVs. Enhanced tumor uptake of EVs and RBCs will be facilitated through the Focus Ultrasound (FUS) technique, which
temporarily permeabilizes the blood-tumor barrier. Tumor targeting and oxygen delivery will be monitored using advanced
molecular imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography
(SPECT). Therapeutic efficacy will be evaluated in relevant tumor models, combining molecular imaging and histopathological
analysis.
The project envisions developing personalized therapies based on autologous patient components, ensuring localized treatment
with reduced side effects. By leveraging the natural compatibility of RBCs and EVs and integrating cutting-edge targeting and delivery
technologies, ERYSO advances the potential of personalized and multimodal cancer therapies.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-SE - HORIZON TMA MSCA Staff Exchanges

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-SE-01

See all projects funded under this call

Coordinator

ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE
Net EU contribution
€ 946 890,00
Address
PASEO MIRAMON 182, PARQUE TECNOLOGICO DE SAN SEBASTIAN EDIFICIO EMPRESARIAL C
20009 San Sebastian
Spain
Region
Noreste País Vasco Gipuzkoa
Activity type
Research Organisations
Links
Total cost
No data

Participants (6)

Partners (7)